ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 18.7
(-1.32%)
TWD 18.7
(-1.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 819.15 Million TWD | -7.5% |
| 2022 | 885.47 Million TWD | 28.24% |
| 2021 | 690.49 Million TWD | -9.93% |
| 2020 | 766.64 Million TWD | 5.07% |
| 2019 | 729.67 Million TWD | -25.27% |
| 2018 | 964.23 Million TWD | -0.82% |
| 2017 | 984.47 Million TWD | -23.78% |
| 2016 | 1.29 Billion TWD | -0.22% |
| 2015 | 1.23 Billion TWD | 20.14% |
| 2014 | 1.09 Billion TWD | -42.2% |
| 2013 | 1.84 Billion TWD | 8.61% |
| 2012 | 1.73 Billion TWD | 14.39% |
| 2011 | 1.48 Billion TWD | -3.07% |
| 2010 | 1.58 Billion TWD | 1.94% |
| 2009 | 1.51 Billion TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 296.44 Million TWD | -3.94% |
| 2024 Q2 | 192.6 Million TWD | -35.05% |
| 2024 Q3 | 31.83 Million TWD | -83.47% |
| 2023 Q2 | 183.55 Million TWD | 7.47% |
| 2023 Q4 | 308.67 Million TWD | 97.8% |
| 2023 Q3 | 156.05 Million TWD | -14.98% |
| 2023 Q1 | 170.8 Million TWD | -29.66% |
| 2023 FY | - TWD | -7.5% |
| 2022 Q3 | 196.15 Million TWD | -22.47% |
| 2022 FY | - TWD | 28.24% |
| 2022 Q2 | 253 Million TWD | 30.77% |
| 2022 Q1 | 193.47 Million TWD | 18.31% |
| 2022 Q4 | 242.84 Million TWD | 23.8% |
| 2021 Q3 | 106.83 Million TWD | -48.78% |
| 2021 FY | - TWD | -9.93% |
| 2021 Q1 | 211.52 Million TWD | 89.56% |
| 2021 Q2 | 208.59 Million TWD | -1.39% |
| 2021 Q4 | 163.53 Million TWD | 53.07% |
| 2020 Q2 | 304.5 Million TWD | 97.8% |
| 2020 Q4 | 111.58 Million TWD | -43.24% |
| 2020 FY | - TWD | 5.07% |
| 2020 Q3 | 196.6 Million TWD | -35.43% |
| 2020 Q1 | 153.95 Million TWD | -4.59% |
| 2019 Q2 | 185.57 Million TWD | -18.04% |
| 2019 Q4 | 161.36 Million TWD | 3.23% |
| 2019 FY | - TWD | -25.27% |
| 2019 Q3 | 156.3 Million TWD | -15.77% |
| 2019 Q1 | 226.42 Million TWD | -9.26% |
| 2018 FY | - TWD | -0.82% |
| 2018 Q4 | 249.53 Million TWD | 8.08% |
| 2018 Q3 | 230.87 Million TWD | -18.65% |
| 2018 Q2 | 283.79 Million TWD | 33.72% |
| 2018 Q1 | 212.23 Million TWD | 3.36% |
| 2017 Q3 | 257.4 Million TWD | 23.6% |
| 2017 FY | - TWD | -23.78% |
| 2017 Q2 | 208.26 Million TWD | -33.56% |
| 2017 Q1 | 313.46 Million TWD | -6.89% |
| 2017 Q4 | 205.34 Million TWD | -20.23% |
| 2016 Q1 | 314.58 Million TWD | -11.58% |
| 2016 FY | - TWD | -0.22% |
| 2016 Q4 | 336.67 Million TWD | 3.6% |
| 2016 Q3 | 324.98 Million TWD | 3.07% |
| 2016 Q2 | 315.3 Million TWD | 0.23% |
| 2015 Q2 | 353.94 Million TWD | 38.0% |
| 2015 FY | - TWD | 20.14% |
| 2015 Q1 | 256.48 Million TWD | 31.56% |
| 2015 Q4 | 355.79 Million TWD | 8.41% |
| 2015 Q3 | 328.2 Million TWD | -7.27% |
| 2014 Q4 | 194.94 Million TWD | -21.32% |
| 2014 Q3 | 247.76 Million TWD | -24.4% |
| 2014 Q2 | 327.72 Million TWD | 6.75% |
| 2014 FY | - TWD | -42.2% |
| 2014 Q1 | 307.01 Million TWD | -21.86% |
| 2013 Q4 | 392.91 Million TWD | 4.24% |
| 2013 FY | - TWD | 8.61% |
| 2013 Q1 | 512.55 Million TWD | -11.96% |
| 2013 Q2 | 581.53 Million TWD | 13.46% |
| 2013 Q3 | 376.94 Million TWD | -35.18% |
| 2012 Q2 | 285.72 Million TWD | -23.23% |
| 2012 Q1 | 372.2 Million TWD | -17.28% |
| 2012 Q4 | 582.21 Million TWD | 20.41% |
| 2012 Q3 | 483.52 Million TWD | 69.23% |
| 2012 FY | - TWD | 14.39% |
| 2011 Q4 | 449.94 Million TWD | 14.41% |
| 2011 FY | - TWD | -3.07% |
| 2011 Q1 | 278.41 Million TWD | -23.66% |
| 2011 Q2 | 378.64 Million TWD | 36.0% |
| 2011 Q3 | 393.26 Million TWD | 3.86% |
| 2010 Q3 | 459.18 Million TWD | 0.0% |
| 2010 FY | - TWD | 1.94% |
| 2010 Q4 | 364.73 Million TWD | -20.57% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Grape King Bio Ltd | 2.88 Billion TWD | 71.606% |
| Standard Chem & Pharm CO., LTD. | 1.57 Billion TWD | 48.121% |
| Maywufa Company Ltd. | 239.81 Million TWD | -241.579% |
| Lotus Pharmaceutical Co., Ltd. | 6.87 Billion TWD | 88.078% |
| LIWANLI Innovation Co., Ltd. | 6.81 Million TWD | -11928.693% |
| YungShin Global Holding Corporation | 1.35 Billion TWD | 39.651% |
| PhytoHealth Corporation | -20.69 Million TWD | 4057.648% |
| SCI Pharmtech, Inc. | 529.61 Million TWD | -54.67% |
| Formosa Laboratories, Inc. | 1.16 Billion TWD | 29.584% |
| PharmaEssentia Corporation | -671.48 Million TWD | 221.991% |
| Bora Pharmaceuticals Co., LTD. | 5.73 Billion TWD | 85.715% |